Shanghai Quiaer Biotechnology

Shanghai Quiaer Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of innovative protein degradation therapies. The company utilizes its proprietary platform to develop Proteolysis Targeting Chimeras (PROTACs) and molecular glues that target disease-causing proteins previously considered undruggable. Quiaer's primary therapeutic focus is oncology, with lead programs targeting the androgen receptor for prostate cancer and BRD4 for various solid tumors. By leveraging deep expertise in medicinal chemistry and protein homeostasis, the company aims to provide next-generation treatments for patients with limited options. Their pipeline includes several candidates in various stages of development, from discovery to early clinical trials.